New hope for aggressive breast cancer: drug combo targets hidden weakness
NCT ID NCT06099769
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 32 times
Summary
This study tests whether enzalutamide, alone or with mifepristone, can control advanced breast cancer that is androgen receptor-positive and triple-negative or low in estrogen receptors. About 201 adults with this aggressive cancer will be randomly assigned to one of these drug combos or standard chemotherapy. The goal is to see which approach delays cancer growth better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute (Data Collection Only)
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••
Contact
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITINGUniondale, New York, 11553, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
RECRUITINGCommack, New York, 11725, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Westchester (All Protocol Activities)
RECRUITINGHarrison, New York, 10604, United States
Contact Phone: •••-•••-••••
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact Phone: •••-•••-••••
-
University of California San Francisco (Data collection only)
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-••••
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-••••
-
University of North Carolina
RECRUITINGChapel Hill, North Carolina, 27514, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.